Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.06%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.64 per share when it actually produced earnings of $2.71, delivering a surprise of 2.65%.Over ...

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change | --- | --- | --- | --- | --- | --- | |---------------------------------------|---------|--------|-------|------------|----------| | Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency | | U.S. | $12,569 | 11,657 | 7.8 % | 7.8 | — | | Europe | 5,214 | 5,131 | 1.6 | 3.4 | (1.8) | | Western Hemisphere excluding U.S. | 1,212 | 1,136 | 6.7 | 22.6 ...

Loading...Loading...Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.The stock is down 5.56% over the past year, -4.16% YTD.Let’s look at what the charts indicate for Johnson & Johnson stock and how the stock currently maps against Wall Street estimates.Johnson & Johnson Technical Setup Ahead Of Q2 Earnings Johnson & Johnson stock is exhibiting a strongly bullish trend, as its ...

Loading...Loading...Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro.Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufactu ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively. J&J will likely ...

Johnson & Johnson (JNJ) will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been ...

SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...

Group 1: Earnings Season Overview - The 2024 Q2 earnings season is underway, with positive expectations for the S&P 500 to show earnings growth [1] - Key reports to watch include those from Netflix, Taiwan Semiconductor, and Johnson & Johnson [1] Group 2: Netflix - Netflix is set to report quarterly results on July 18, with shares recovering to near all-time highs after a previous earnings drop [2] - Total subscribers reached 269.6 million, marking a 16% year-over-year increase, with four consecutive beats in subscriber additions [2] - Earnings per share (EPS) is expected to grow by 43% on 17% higher sales, reflecting improved profitability and higher margins [3] Group 3: Taiwan Semiconductor - Taiwan Semiconductor (TSM) shares have increased over 80% in 2024, driven by the AI chip demand [5] - Earnings estimate for the quarter is $1.37 per share, indicating a 20% increase year-over-year, while sales are expected to reach $20.2 billion, up 5% [5] - TSM announced a 10% increase in its quarterly payout to $0.45 per share, appealing to income-focused investors [7] Group 4: Johnson & Johnson - Johnson & Johnson has seen stagnant share performance over the last three years, with a 4% overall loss, but has consistently exceeded EPS estimates [8] - The Zacks Consensus EPS estimate for the upcoming release is $2.71, down 1% since mid-April, with revenue expectations at $22.4 billion, suggesting a 12% decline year-over-year [9] - JNJ is scheduled to report on July 17, before market opens [9]

Core Insights - Johnson & Johnson (JNJ) is expected to report quarterly earnings of $2.71 per share, reflecting a decline of 3.2% year over year, with revenues forecasted at $22.38 billion, a decrease of 12.3% year over year [1] - Analysts have revised the consensus EPS estimate down by 0.3% over the last 30 days, indicating a reassessment of initial forecasts [1] - The relationship between earnings estimate trends and short-term stock price movements is well-documented [1] Sales Projections - Analysts project 'Sales- MedTech- Total' to reach $8.21 billion, indicating a year-over-year increase of 5.4% [2] - 'Sales- Innovative Medicine- WW' is expected to be $14.18 billion, reflecting a 3.2% increase year over year [2] - 'Sales- MedTech- Orthopaedics- Trauma- WW' is estimated at $764.77 million, showing a 3.5% increase from the previous year [2] Detailed Sales Estimates - 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' is projected at $780.35 million, a 1.9% increase year over year [3] - 'Sales- MedTech- Orthopaedics- Hips- US' is expected to be $261.14 million, indicating a 4.5% increase [3] - 'Sales- MedTech- Orthopaedics- Hips- International' is forecasted at $146.40 million, reflecting a slight decline of 0.4% [3] - 'Sales- MedTech- Orthopaedics- Knees- US' is estimated at $226.07 million, a 2.3% increase [3] - 'Sales- MedTech- Orthopaedics- Knees- International' is projected at $149.67 million, indicating a 5.4% increase [3] Additional Sales Insights - 'Sales- MedTech- Orthopaedics- Trauma- US' is expected to reach $498.64 million, a 3.2% increase year over year [4] - 'Sales- MedTech- Orthopaedics- Trauma- International' is projected at $267.83 million, reflecting a 5% increase [4] - 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- US' is estimated at $440.94 million, indicating a 1.8% increase [4] - Organic Sales Growth (Operational growth) is expected to be 4.9%, down from 7.5% in the same quarter last year [4] Stock Performance - Johnson & Johnson shares have increased by 2.9% over the past month, compared to a 4.3% increase in the Zacks S&P 500 composite [4]